2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|June 26, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-07-02-2014
- Volume 10
- Issue 7
Jones Packaging Invests in New Solid Dose Vial Line
Author(s)Pharmaceutical Technology Editors
Jones Packaging introduces a new solid dose vial line in its Toronto facility.
Advertisement
The fully integrated line also includes carding and blistering for a market-ready packaging solution. The Jones Printed Packaging division designs and manufactures the card and label components in-house for tighter control over timelines, costs, and quality. Jones services the entire North American market.
Source:
Articles in this issue
over 12 years ago
GSK Offers $1 Million Award for Healthcare Innovationsover 12 years ago
Covance MarketPlace Connects Biotech with Potential Partnersover 12 years ago
Pharma Capacity to Produce Cytotoxic Injectable Drugs Constrictsover 12 years ago
Changing Market Dynamics Require New Approaches to Innovationover 12 years ago
Cost Is No Longer the Driving Force for Outsourcingover 12 years ago
Cytovance Biologics Manufactures AM0010 for ARMO BioSciencesover 12 years ago
Globalization Challenges Drug Regulatorsover 12 years ago
Aesica Pharmaceuticals S.r.I. Implements Serialization Systemover 12 years ago
Frontage Labs Plans Expansion of CMC Facilityover 12 years ago
Novartis Hosts 13th Annual Malaria Expert PanelAdvertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement